Skip to content
MarketScale
‹ Back to IndustriesSciences

The Future: Computers That Use Light, Not Electricity

The last half-century of personal computer design and development has been a continual quest to create a faster and more powerful device. Improvements in hardware have been remarkable, but now computing speed is being limited by the transmission of electricity through the very wires that connect components. That’s why engineers are now developing computers that…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
The Future: Computers That Use Light, Not Electricity

Key takeaways

01

The last half-century of personal computer design and development has been a continual quest to create a faster and more powerful device.

02

Improvements in hardware have been remarkable, but now computing speed is being limited by the transmission of electricity through the very wires that connect components.

03

That’s why engineers are now developing computers that…

The last half-century of personal computer design and development has been a continual quest to create a faster and more powerful device. Improvements in hardware have been remarkable, but now computing speed is being limited by the transmission of electricity through the very wires that connect components. That’s why engineers are now developing computers that use light rather than electricity to transmit information. Let’s take a closer look at the future role that light could play in powering computers.

Computing at the Speed of Light

Conventional computers employ electronic circuits that switch on and off to process information via electrons. Data is transmitted to microprocessors and memory storage devices through microscopic wires. However, the laws of physics are now limiting the degree to which these components can be improved. That’s why scientists and engineers are turning to optical computing.

In optical computing, calculations are performed by beams of photons instead of streams of electrons. These light beams interact with each other, guided by optical components such as lenses and beam splitters. Unlike electrons, which must overcome the resistance of flowing through physical circuitry, photons have no mass, allowing them to travel at the speed of light, creating greater efficiency and less heat in the process.

Breakthroughs in Materials Are Helping Make Optical Computing Possible

The available materials have limited progress in optical computing; however, a number of breakthroughs in recent years have opened new possibilities. Scientists have recently found a way to modify a type of glass called chalcogenide to conduct both positive and negative charges, making it compatible with existing computing technology. This will allow the material to conduct light across a wide range of bandwidths.

Researchers are also working on a material call light-induced magnetoresistive RAM, or LI-RAM, which will allow the creation of a photonic computer chip that exists at the molecular level. LI-RAM uses 10 percent less power than conventional RAM, produces virtually no heat, and has a much longer life.

Computing with Light Will Create Exciting New Possibilities

Optical computing is expected to create new opportunities in deep learning, which has contributed to recent advances in Artificial Intelligence. Deep learning involves feeding vast data sets into self-learning systems that use data mining, pattern recognition, and natural language processing to mimic the way the human brain works. This process requires an enormous amount of computing power and speed that only light-based computing can provide. These new capabilities should drive breakthroughs in areas such as machine learning, natural language processing, speech recognition, and human-computer interaction, allowing artificial neural networks that can learn to perform complex tasks such as facial recognition, stock market predictions, medical diagnoses, and autonomous driving.

Fiberguide Has the Components Needed for Computing with Light

For more than three decades Fiberguide Industries has been a reliable, long-term, strategic partner with OEM manufacturers, providing efficient, cost-effective, practical fiber optic solutions engineered to meet their specific needs. We specialize in manufacturing large core specialty optical fiber, high temperature metalized optical fibers, and we package these fibers in a variety of assemblies and bundles used for optical power delivery and optical sensing applications.

Read more at fiberguide.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512